Center-Authored Papers

Filters: Author is Fuchs, Jonathan D  [Clear All Filters]
A
Adamson BJS, Fuchs JD, Sopher CJ, Flood DM, Johnson PR, Haynes BF, Kublin JG.  2015.  A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines.. Clinical and translational science. 8(2):166-8. Abstract
F
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract
Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B et al..  2013.  Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.. Journal of acquired immune deficiency syndromes (1999). Abstract
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD et al..  2015.  First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).. Open forum infectious diseases. 2(3):ofv082. Abstract
G
Gorse GJ, Newman MJ, DeCamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL.  2012.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.. Clinical and vaccine immunology : CVI. 19(5):649-58. Abstract
J
Jacob ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs JD et al..  2011.  A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial.. AIDS and behavior. 15(5):897-904. Abstract
P
Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M et al..  2010.  The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.. Science (New York, N.Y.). 330(6010):1551-7. Abstract
S
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract